CV 17
Alternative Names: CP-ASO; CV-17Latest Information Update: 24 Apr 2023
At a glance
- Originator Cellivery
- Class Antisense oligonucleotides
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders
Most Recent Events
- 24 Apr 2023 Preclinical trials in Neurodegenerative disorders in South Korea (Intraspinal) (Celllivery pipeline, April 2023)